According to an exchange filing, on March 26, Sanofi India Limited, Sanofi Healthcare India Private Limited, and Cipla Limited established an exclusive distribution and marketing collaboration for the sale and promotion of Sanofi India’s Central Nervous System (CNS) product portfolio in India.
Cipla will manage the distribution of Sanofi India’s six CNS brands as part of this partnership, including the market-leading Frisium® brand of anti-epileptic medications.
)
Rodolfo Hrosz, Managing Director at Sanofi India Limited, stated, “Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve the lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across India”.
Achin Gupta, Chief Executive Officer at One India Business, Cipla Limited, added, “Enhancing access to high-quality treatments is central to our purpose of ‘Caring for Life’. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients”.
